These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 9276430)

  • 1. Subtyping of human immunodeficiency virus type 1 strains by using antibodies specific for the third variable domain (V3) of gp120: results may be affected by divergent V3 sequences.
    Sherefa K; Sällberg M; Johansson B; Salminen M; Sönnerborg A
    J Clin Microbiol; 1997 Sep; 35(9):2419-21. PubMed ID: 9276430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence of no change in V3 loop antibody recognition pattern in HIV type 1-infected Ethiopians between 1988 and 1993.
    Sherefa K; Sällberg M; Sönnerborg A
    AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1551-6. PubMed ID: 7534097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evaluation of diagnostic efficiency of the recombinant protein modeling immunodominant epitope V3 of envelope gp120 for immunoenzyme detection for HIV-1 infection antibodies].
    Riabinina SA; Baranova EN; Sharipova IN; Susekina MI; Puzyrev VF; Obriadina AP; Burkov AN; Ulanova TI
    Mol Gen Mikrobiol Virusol; 2007; (3):33-6. PubMed ID: 17886471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variant-specific monoclonal and group-specific polyclonal human immunodeficiency virus type 1 neutralizing antibodies raised with synthetic peptides from the gp120 third variable domain.
    Laman JD; Schellekens MM; Abacioglu YH; Lewis GK; Tersmette M; Fouchier RA; Langedijk JP; Claassen E; Boersma WJ
    J Virol; 1992 Mar; 66(3):1823-31. PubMed ID: 1637373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pattern of antibody response against the V3 loop in children with vertically acquired immunodeficiency virus type 1 (HIV-1) infection.
    De Rossi A; Zanotto C; Mammano F; Ometto L; Del Mistro A; Chieco-Bianchi L
    AIDS Res Hum Retroviruses; 1993 Mar; 9(3):221-8. PubMed ID: 7682425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of correlation between V3-loop peptide enzyme immunoassay serologic subtyping and genetic sequencing.
    Nkengasong JN; Willems B; Janssens W; Cheingsong-Popov R; Heyndrickx L; Barin F; Ondoa P; Fransen K; Goudsmit J; van der Groen G
    AIDS; 1998 Aug; 12(12):1405-12. PubMed ID: 9727560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. V3 serological subtyping of human immunodeficiency virus type 2 infection is not relevant.
    Plantier JC; Damond F; Souquières S; Brun-Vézinet F; Simon F; Barin F
    J Clin Microbiol; 2001 Oct; 39(10):3803-7. PubMed ID: 11574625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Presentation of native epitopes in the V1/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains.
    Kayman SC; Wu Z; Revesz K; Chen H; Kopelman R; Pinter A
    J Virol; 1994 Jan; 68(1):400-10. PubMed ID: 7504740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reactions of Ugandan antisera with peptides encoded by V3 loop epitopes of human immunodeficiency virus type 1.
    Smith JD; Bruce CB; Featherstone AS; Downing RG; Biryahawaho B; Clegg JC; Carswell JW; Oram JD
    AIDS Res Hum Retroviruses; 1994 May; 10(5):577-83. PubMed ID: 7522494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A survey of synthetic HIV-1 peptides with natural and chimeric sequences for differential reactivity with Zimbabwean, Tanzanian and Swedish HIV-1-positive sera.
    Blomberg J; Lawoko A; Pipkorn R; Moyo S; Malmvall BE; Shao J; Dash R; Tswana S
    AIDS; 1993 Jun; 7(6):759-67. PubMed ID: 8363754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diversity of antibody binding to V3 peptides representing consensus sequences of HIV type 1 genotypes A to E: an approach for HIV type 1 serological subtyping.
    Barin F; Lahbabi Y; Buzelay L; Lejeune B; Baillou-Beaufils A; Denis F; Mathiot C; M'Boup S; Vithayasai V; Dietrich U; Goudeau A
    AIDS Res Hum Retroviruses; 1996 Sep; 12(13):1279-89. PubMed ID: 8870850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. V3 serotyping of HIV-1 infection: correlation with genotyping and limitations.
    Plantier JC; Damond F; Lasky M; Sankalé JL; Apetrei C; Peeters M; Buzelay L; M'Boup S; Kanki P; Delaporte E; Simon F; Barin F
    J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Apr; 20(5):432-41. PubMed ID: 10225224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The V3-directed immune response in natural human immunodeficiency virus type 1 infection is predominantly directed against a variable, discontinuous epitope presented by the gp120 V3 domain.
    Schreiber M; Wachsmuth C; Müller H; Odemuyiwa S; Schmitz H; Meyer S; Meyer B; Schneider-Mergener J
    J Virol; 1997 Dec; 71(12):9198-205. PubMed ID: 9371578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV type 1 V3 serotyping of Tanzanian samples: probable reasons for mismatching with genetic subtyping.
    Hoelscher M; Hanker S; Barin F; Cheingsong-Popov R; Dietrich U; Jordan-Harder B; Olaleye D; Nägele E; Markuzzi A; Mwakagile D; Minja F; Weber J; Gürtler L; Von Sonnenburg F
    AIDS Res Hum Retroviruses; 1998 Jan; 14(2):139-49. PubMed ID: 9462924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid grouping of HIV-1 infection in subtypes A to E by V3 peptide serotyping and its relation to sequence analysis.
    Sherefa K; Sönnerborg A; Steinbergs J; Sällberg M
    Biochem Biophys Res Commun; 1994 Dec; 205(3):1658-64. PubMed ID: 7811250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptides mimicking selected disulfide loops in HIV-1 gp120, other than V3, do not elicit virus-neutralizing antibodies.
    Neurath AR; Strick N; Fields R; Jiang S
    AIDS Res Hum Retroviruses; 1991 Aug; 7(8):657-62. PubMed ID: 1718344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Examination of sera from human immunodeficiency virus type 1 (HIV-1)-infected individuals for antibodies reactive with peptides corresponding to the principal neutralizing determinant of HIV-1 gp120 and for in vitro neutralizing activity.
    Warren RQ; Anderson SA; Nkya WM; Shao JF; Hendrix CW; Melcher GP; Redfield RR; Kennedy RC
    J Virol; 1992 Sep; 66(9):5210-5. PubMed ID: 1380094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serotyping HIV-1 with V3 peptides: detection of high avidity antibodies presenting clade-specific reactivity.
    Casseb J; Katzenstein D; Winters M; Brigido LF; Duarte AJ; Hendry RM
    Braz J Med Biol Res; 2002 Mar; 35(3):369-75. PubMed ID: 11887216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. V3 loop core region serotyping of HIV-1 infected patients using the FHV epitope presenting system.
    Schiappacassi M; Buratti E; D'Agaro P; Ciani L; Scodeller ES; Tisminetzky SG; Baralle FE
    J Virol Methods; 1997 Jan; 63(1-2):121-7. PubMed ID: 9015282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunological reactivity of a human immunodeficiency virus type I derived peptide representing a consensus sequence of the GP120 major neutralizing region V3.
    Wagner R; Modrow S; Böltz T; Fliessbach H; Niedrig M; von Brunn A; Wolf H
    Arch Virol; 1992; 127(1-4):139-52. PubMed ID: 1456889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.